Dong Joon Kim PhD.

Education:

1995-1999 (B.S.) College of Agricultural Life Science, Chungnam National University, Korea

1999-2003 (M.S.) College of Agricultural Life Science, Chungnam National University, Korea

Dissertation: Gene Expression Analysis of an Ovarian Cancer Cell Line over-Expressing Human R-PTP-k using cDNA Microarray

2003-2007 (Ph.D.)College of Pharmacy, Chungnam National University

Dissertation: Identification and Characterization of Lysyl Oxidase Like 4 as a Novel target of Transforming Growth Factorb1 Signaling in Human Hepatocellular Carcinoma Cell line

Academic / Research Experience

2001. 9. - 2007. 2.Training researcher, biotechnology researcher, Korea

2007. 3 – 2008. 6.Post-doctor,biotechnology researcher, Korea

2008. 7. – 2012. 5.Post-doctor, The Hormel Institute, University of Minnesota

2012. 5. – 2014. 5.Post-doctor, Basic Technique Research Group

2012. 5 – present Post-doctor researcher, biological technique researcher, Korea

AWARDS& HONORS

2012.5 – 2014.5 Research Fellowship for Young Scientists

2008.7 –2012.5 Post-doctoral Research fellowship,The Hormel Institute

2007 – 2008.6 Post-doctoral Research fellowship,Medical Media Research Center

2001.3–2001.9 Graduate Academic Excellent Scholarship Award,Chungnam National University

1995.9-1998.3 Undergraduate Academic Excellent Scholarship Award, Chungnam National University

Publication (selected):

1. Kim DJ, Lee MH, Shim JH, Carper A, Bode AM and Dong Z.2015. Herbacetin suppresses skin tumor growth through targeting ODC.(Prepare manuscript).

2. Kim DJ, Lee MH, Oi N, Kim MO, Bode AM and Dong Z.2015. Direct targeting of COX2 by DIM prevents colon cancer.(Prepare manuscript).

3. Kim DJ, Roh E, Lee MH, Oi N, Lim DY, Kim MO, Cho YY, Pugliese A, Shim JH, Chen H, Cho EJ, Kim JE, Kang SC, Paul S, Kang HE, Jung JW, Lee SY, Kim SH, Reddy K, Yeom YI, Bode AM and Dong Z.2015. Herbacetin is a novel allosteric inhibitor of ornithine decarboxylase with antitumor activity.Cancer Research.(Accepted) IF-9.329 SCI, ISSN: 00085472, Publisher: American Association for Cancer Research

4. Kim DJ, Park YS, Kang MG, You Y, Jung Y, Koo H, Kim J, Kim M, Hong S, Park KC and Yeom YI.,2015. Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine chemoresistance in pancreatic cancer cells.Experimental Cell Research.

1;336(1):119-29. IF-3.246 2015-08-01 SCI, ISSN: 00144827, Publisher: Elseviera

5. Kim DJ, Park YS, Kim ND, Min SH, You Y, Jung Y, Koo H, Noh H, Kim J, Park KC and Yeom YI.2015. A Novel Pyruvate Kinase M2 Activator Compound that Suppresses Lung Cancer Cell Viability under Hypoxia.Molecules and Cells. 30;38(4):373-9 IF-2.09 2015-04-01 SCI, ISSN: 10168478 Publisher: Korean Society for Molecular and Cellular Biology

6. Lee MH*, Huang Z*,Kim DJ*, Kim SH*, Kim MO, Lee SY, Xie H, Par SJ, Kim JY, Kundu JK, Bode AB, Surth YJ and Dong Z.2013. Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth.Cancer Prevention Research (Phila). 6(5):455-65. IF-4.444 2013-05-01 SCIE, ISSN: 19406207, Publisher: American Association for Cancer Research

7. Kim DJ*, Lee MH*, Reddy S, Li Y, Lim DY, Xie H, Lee SY, Yeom YI, Bode AM and Dong Z.2013. CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.Carcinogenesis 34(5):1134-43 IF-5.334 2013-05-01 SCI, ISSN: 01433334, Publisher: Oxford University Press

8. Kim DJ, Li Y, Reddy K, Lee MH, Kim MO, Cho YY, Lee SY, Kim JE, Bode AM and Dong Z.2012. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.Cancer Research. 15;72(12):3060-8. IF-9.329 2012-06-01 SCI, ISSN: 00085472, Publisher: American Association for Cancer Research

9. Kim DJ, Reddy K, Kim MO, Li Y, Nadas J, Cho YY, Kim JE, Shim J, Song NR, Carper A, Lubert RA, Bode AM, Dong Z.2011. (3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon cancer growth in vitro and in vivo.Cancer Prevention Research (Phila). 4(11):1842-51. IF-4.444 2011-11-01 SCIE, ISSN: 19406207, Publisher: American Association for Cancer Research

10. Urusova D*, Shim J*,Kim DJ*, Jung SK*, Zykova T, Carper A, Bode AM, Dong Z.2011. Epigallocatechin-gallate suppresses tumorigenesis by directly targeting Pin1.Cancer Prevtion Research (Phila). 4(9):1366-77. IF-4.444 2011-09-01 SCIE, ISSN: 19406207, Publisher: American Association for Cancer Research